DLBCL is defined as a B-cell neoplasm with a diffuse growth pattern of large tumor cells with a nuclear size larger than that of a histiocyte nucleus or more than twice that of a normal small lymphocyte. Although in general DLBCL shows aggressive clinical behaviors, there is a spectrum of ...
Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin's lymphoma, is clinically heterogeneous: 40% of patients respond well to current therapy and have prolonged survival, whereas the remainder succumb to the disease. We proposed
Administration of axicabtagene ciloleucel (axi-cel; Yescarta) as treatment for patients with large B-cell lymphoma (LBCL) resulted in a significantly longer overall survival (OS) rate when compared to a standard, multistep treatment, according to a new study published inThe New...
The International Prognostic Index is predictive of survival. Only about 40% of patients with diffuse large B-cell lymphoma are cured with polychemotherapy. Gene expression profiling has recently been introduced to develop molecularly distinct portraits of diffuse large B-cell lymphoma (and, ...
There are three large groups: the B cell, T cell, and natural killer cell tumors. Newer techniques such as immunophenotyping (a way to study the proteins on a cell and identify the precise types of B or T cells that are involved) diagnose and classify lymphomas. This technique is ...
Patients with refractory large B-cell lymphoma who were treated with Axi-cel had a 3-year overall survival rate of 47%, according to an updated analysis of the phase II ZUMA-1 trial.
Several gene-expression signatures can be used to predict the prognosis in diffuse large-B-cell lymphoma, but the lack of practical tests for a genome-scale analysis has restricted the use of this method.We studied 36 genes whose expression had been reported to predict survival in diffuse large...
The standard treatment for the disease is a combination of chemotherapy drugs plus rituximab, a drug known as a monoclonal antibody. Previously, researchers classified patients into those with activated B-cell-like (ABC) DLBCL, with about a 40 percent average survival rate, and those with germinal...
Lymph node–based disease without Waldenström macroglobulinemia: median survival, 4 years Differential Diagnosis ▪ Reactive lymphoid hyperplasia, particularly autoimmune disease associated lymphadenitis, IgG4 related sclerosing–autoimmune disorder, and plasma cell variant Castleman disease ▪ B-cell small...
Davis et al., “Constitutive Nuclear Factor kB Activity is Required for Survival of Activated B Cell-like Diffuse Large B Cell Lymphoma Cells,” J. Exp. Med., 194 (12),1861-1874 (2001). Delmer et al., “Overexpression of Cyclin D2 Chronic B-Cell Malignancies,” Blood, 85 (10), ...